Regimen Reference Order – GAST – cetuximab

ARIA: GAST - [cetuximab]

Planned Course: **Weekly until disease progression or unacceptable toxicity (1 cycle = 8 doses)**
Indication for Use: **Colorectal Cancer Metastatic**

CVAD: At Provider's Discretion

Proceed with treatment if:
ANC equal to or greater than 1.5 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L
- **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GAST – cetuximab

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Dose 1		
dexamethasone	8 mg	IV in normal saline 50 mL over 15 minutes
diphenhydrAMINE	50 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medication(s) before starting cetuximab		
cetuximab	400 mg/m^2 Loading Dose	IV over 2 hours (administered undiluted) Doses greater than 1200 mg must be administered over 2.5 hours *Use 0.2 or 0.22 micron filter* **Alert:* Pharmacy to ensure final volume on label* **Nursing Alert:* IV tubing is primed with cetuximab*
Dose 2		
dexamethasone	8 mg	IV in normal saline 50 mL over 15 minutes
diphenhydrAMINE	50 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medication(s) before starting cetuximab		
cetuximab	250 mg/m^2	IV over 1 hour (administered undiluted) Doses greater than 600 mg must be administered over 2 hours *Use 0.2 or 0.22 micron filter* **Alert:* Pharmacy to ensure final volume on label* **Nursing Alert:* IV tubing is primed with cetuximab*

Dose 3 and Onwards		
cetirizine	10 mg	Orally 30 minutes prior to cetuximab
dexamethasone	8 mg	IV in normal saline 50 mL over 15 minutes
Wait 30 minutes after completion of IV pre-medication(s) before starting cetuximab		
cetuximab	250 mg/m^2	IV over 1 hour (administered undiluted) Doses greater than 600 mg must be administered over 2 hours *Use 0.2 or 0.22 micron filter* **Alert:* *Pharmacy to ensure final volume on label* **Nursing Alert:* *IV tubing is primed with cetuximab*
All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

All Doses

- Clinical assessment for cetuximab-related skin toxicity

Doses 1 and 2

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline, after 1-hour observation and as clinically indicated
- Observe patient for 1 hour after cetuximab infusion. Full vital signs prior to discharge

Dose 3 and Onwards

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- For patients with no prior reactions to cetuximab, no observation period is required. Patient can be discharged from treatment room if stable
- For patients who have had a previous reaction to cetuximab, observe patient for 1 hour after cetuximab infusion. Full vital signs after 1-hour observation

All Cycles

- CBC, serum creatinine, urea, liver enzymes, magnesium, calcium and albumin as per Physician Orders
- Weekly blood work not required

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Sunscreen	Broad-spectrum, Minimum SPF 15 (PABA free, zinc oxide or titanium dioxide preferred)	Apply liberally to exposed skin 30 minutes before going outdoors. Reapply every 2 hours and after swimming
Moisturizing lotion	Fragrance-free	Apply topically to face, hands, feet, neck, back and chest daily in the morning on rising and **as needed**
In the event of a cetuximab-induced skin rash:		
doxycycline	100 mg	Orally twice daily as directed by clinic
hydrocortisone cream	1%	Apply topically daily at bedtime to face, hands, feet, neck, back and chest as directed by clinic

DISCHARGE INSTRUCTIONS

- Warn patients of the possibility of a late onset reaction to cetuximab as reactions may occur several hours after infusion or with subsequent infusions
- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to use recommended support medications

ADDITIONAL INFORMATION

- cetuximab causes dermatological and nail changes
- cetuximab can cause hypomagnesemia
- cetuximab can cause interstitial lung disease, pneumonitis and exacerbation of pre-existing fibrotic lung disease
- Administration site restrictions are in place for cetuximab. Dose 1 of cetuximab should only be administered at CCMB MacCharles or Tache in Winnipeg